Corbus Pharmaceuticals Holdings Inc
Change company Symbol lookup
Select an option...
CRBP Corbus Pharmaceuticals Holdings Inc
PTI Proteostasis Therapeutics Inc
CALB California BanCorp
$NOPM2 Refinitiv Norway Metal & Mining Inde
EBAY eBay Inc
PTON Peloton Interactive Inc
GO Grocery Outlet Holding Corp
NUE Nucor Corp
SJM J M Smucker Co
KR Kroger Co
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Postmarket

Last Trade
Delayed
$1.20
-0.02 (-1.64%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.22
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.26
Day's Low
1.18
Volume
(Light)
Volume:
3,095,669

10-day average volume:
4,789,899
3,095,669

Tesla scores a 'distant second' to GM in new study

1:38 pm ET October 28, 2020 (MarketWatch)
Print

Shawn Langlois

Elon Musk once tweeted (https://twitter.com/elonmusk/status/1001954916569579520) that, "Consumer Reports is always fair & accurate in their criticism." We'll see if he sticks with that take after the publication's latest study gave a nod to one of Tesla's top rivals.

According to testing results from Consumer Reports (https://www.consumerreports.org/car-safety/cadillac-super-cruise-outperforms-other-active-driving-assistance-systems/#2), Tesla's (TSLA) Autopilot system placed a "distant second" to GM (GM), scoring 57 out of 100 points, compared with 69 for the Detroit auto maker.

To determine the rankings, Consumer Reports put 17 of the newest driving assistance systems to the test on a private track and on public roads, rating them by dozens of measures, including steering the car, controlling the speed, ease of use and keeping the driver safe and engaged.

"Even with new systems from many different automakers, [GM's] Super Cruise still comes out on top due to the infrared camera ensuring the driver's eyes are looking toward the roadway," Consumer Reports' Kelly Funkhouser said in reference to the results.

Here's how the top eight placed:

This isn't the first time GM's Super Cruise has beat out Tesla. It also happened the last time these systems were tested back in 2018.

"Even after two years, Cadillac's Super Cruise remained our top-rated system because, when turned on, it uses direct driver monitoring to warn drivers that appear to have stopped paying attention to the road," Consumer Reports explained.

GM has said 22 vehicles will come equipped with Super Cruise by 2023, including a next-generation system with greater capabilities.

Tesla did not immediately respond to a request for comment, and, at last check, Musk had yet to address the results on Twitter (TWTR).

-Shawn Langlois; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 28, 2020 13:38 ET (17:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.